. 2014 Sep;58(9):5576–5580. doi: 10.1128/AAC.02681-14

TABLE 2.

Results for screening of bacteria recovered from TCF and CV for the presence of resistant strains at the end of therapy (day 11)

Treatment group (no. of samples)^a	No. of samples with resistant strains/total no. of samples (%)^c from:		MIC (mg/liter) of resistant strains isolated
Treatment group (no. of samples)^a	TCF	CV	MIC (mg/liter) of resistant strains isolated
Control (21)^b	0	0
CXA (20)	0	0
DAP (22)	35	35	2–3
RIF (19)	88	88	2–4
CXA + DAP (20)^b	0	0
CXA + RIF (20)	0	0

CXA, cloxacillin; DAP, daptomycin; RIF, rifampin.

We did not detect subpopulations of daptomycin with MICs of ≥0.5 mg/liter among the wild-type strain (ATCC 29213) or among strains recovered ex vivo from the control or daptomycin-cloxacillin group.

Screening of resistant strains recovered from TCF and CV was performed using the methodology previously described (10,16), with agar plates containing 1 μg/ml cloxacillin, rifampin, or daptomycin. Results were interpreted as positive (some macroscopic growth) or negative (no growth).